| 영문 | prostate gland | 한글 | 전립샘 |
|---|---|---|---|
| 설명 | 남성생식기의 외분비샘의 일종으로, 방광의 목부분과 요도를 둘러싸고 있다. 전립샘은 정액을 만드는 전립샘액을 분비하며 5개의 엽으로 구성되어 있다. |
||
| 영문 | muscular system | 한글 | 근육계통 |
|---|---|---|---|
| 설명 | 근육에 의해 이루어진 하나의 계통을 임의적으로 나누어 부른 말. |
||
| 영문 | muscular dystrophy | 한글 | 근육퇴행위축 |
|---|---|---|---|
| 설명 | 근섬유의 파괴로 인한 점진적인 근위축과 허약을 특징으로 하는 일련의 선천적인 질환군을 통털어 말한다. 대표적인 경우가 뒤쉔(Duchenne)형으로 성염색체 열성유전을 하며, 대개 4 세이내에 발병해 청년기를 넘기는 경우가 드물다. 특징적 소견으로 장딴지근(gastronemius)의 거짓비대(pseudohypertrophy)(실제적으로는 근위축이 일어나지만, 근섬유 대신에 지방세포가 들어차 도리어 마치 근육이 증가한 것처럼 보이는 현상) 소견을 볼 수 있다. |
||
| PMD | Progressive Muscular Dystrophy; 진행성 근이영양증 Types of PMD(Progressive Muscular Dystroph... |
|---|---|
| CMD | campomelic dysplasia; camptomelic dwarfism; cartilage matrix deficiency; chief medical director; chi... |
| MSS | Marshall-Smith syndrome; massage; Medical Superintendents' Society; Medicare Statistical System; men... |
| MIS | management information system; medical information service; meiosis-inducing substance; minimally in... |
| BPH | Benign Prostate(Prostatic) Hypertrophy(Hyperplasia); 전립선 비대(증) |
| BMD | Becker Muscular Dystrophy |
|---|---|
| CMD | Congenital muscular dystrophies |
| CMD | Congenital muscular dystrophy |
| CMT | Congenital muscular torticollis |
| DMD | Duchene muscular dystrophy |
| muscular substance of prostate | The smooth muscle in the stroma of the prostate. Synonym: substantia muscularis prostatae, musculus prostaticus. (05 Mar 2000) |
|---|
| glandular substance of prostate | The glandular tissue of the prostate as distinct from the stroma and capsule. Synonym: substantia glandularis prostatae. (05 Mar 2000) |
|---|---|
| amyloid bodies of the prostate | An obsolete term for small masses of colloid material often present in the tubules of the gland. See: corpus amylaceum. (05 Mar 2000) |
| anterior surface of prostate | The anterior surface of the prostate. Synonym: facies anterior prostatae. (05 Mar 2000) |
| apex of prostate | The lowermost part of the prostate, situated above the urogenital diaphragm. Synonym: apex prostatae. (05 Mar 2000) |
| base of prostate | The broad upper surface of the prostate contiguous with the bladder wall. Synonym: basis prostatae. (05 Mar 2000) |
| cancer, prostate | Cancer of the gland that produces some of the components of semen fluid. Prostate cancer is the second leading cause of death of males in the U.S. Prostate cancer is often first detected as a hard nodule during a routine rectal examination. The PSA blood test is a screening test for prostate cancer. Diagnosis of prostate cancer is established when cancer cells are identified in prostate tissue obtained by a biopsy. In some patients, prostate cancer is life threatening. In many others, prostate cancer can exist for years without causing any health problems. Treatment options for prostate cancer include observation, radiation therapy, surgery, hormonal therapy, and chemotherapy. (12 Dec 1998) |
| middle lobe of prostate | The portion of the prostate lying between the urethra and the ejaculatory ducts; indistinct unless hypertrophied. Synonym: lobus medius prostatae, Morgagni's caruncle. (05 Mar 2000) |
| posterior surface of prostate | The posterior surface of the prostate. Synonym: facies posterior prostatae. (05 Mar 2000) |
| prostate | A small conical gland at the base of the male bladder and surrounding the first part of the urethra. (27 Sep 1997) |
| prostate acid phosphatase | An enzyme produced by the prostate that is elevated in some patients with prostate cancer. (12 Dec 1998) |
| prostate anatomy | <radiology> Periurethral glandular tissue, may lead to BPH, prostatic acinar tissue, central zone may lead to BPH, peripheral zone may lead to carcinoma (12 Dec 1998) |
| prostate cancer | The second most common malignancy in men. A malignant tumour of glandular origin in the prostate. Over 95% are adenocarcinomas. Most commonly seen in older men, with the age of 73 being the average age at the time of diagnosis. A family history for prostate cancer and perhaps, a diet that is high is fat are considered to be risk factors for this malignancy. Early detection is possible through annual digital rectal examinations and routine PSA testing. (27 Sep 1997) |
| prostate carcinoma | <radiology> Treatment: stages A and B: radical prostatectomy (prostate, seminal vesicles, part of bladder); some do simple prostatectomy for stage A, stage C: radiation therapy, stage D: orchiectomy and/or oestrogens stage A Tumour discovered incidentally in tissue removed for BPH, A1 Small focal involvement of one lobe, A2 Multifocal or diffuse carcinoma, Stage B Palpable carcinoma confined to prostate on digital exam, B1 Solitary nodule less than 1.5 cm, B2 Diffuse involvement of both lobes, Stage C Tumour extending through the prostate capsule; no metastasis, Stage D Metastases, usually to bone and/or pelvic lymph nodes (12 Dec 1998) |
| prostate gland | A gland in the male that surrounds the neck of the bladder and urethra. The prostate contributes to the seminal fluid. (16 Dec 1997) |
| prostate-specific antigen | <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer. It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease. It is found in normal seminal fluid and produced by the prostatic epithelial cells. Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition. No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain. Acronym: PSA Registry number: EC 3.4.21.77 (22 Sep 2002) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|